Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens

Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens

BackgroundPembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of...

Full description

Bibliographic Details
Main Authors: Ken Saijo, Hiroo Imai, Kota Ouchi, Keiju Sasaki, Yuya Yoshida, Yoshifumi Kawamura, Sakura Taniguchi, Yuki Kasahara, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
immune check point inhibitor
pembrolizumab
head and neck cancer
depth of response
predictive factor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1230731/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1230731/full

Similar Items